Satraplatin

Research use only, not for human use.

Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis.

Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis; shows similar cytotoxicity and pattern of cytotoxicity to cisplatin against human ovarian carcinoma cell lines (IC50=1.7 uM); shows antitumor selectivity far superior to cisplatin, carboplatin, or tetraplatin in vivo; orally active.Chemotherapeutic Agents, Phase 2 Clinical(In Vitro):Satraplatin needs to avoid light in the solution, and it is unstable in the alkaline state but stable in the acidic state.Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC50 of 1.36 ± 0.11 μM. Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC50, 7.04 μM), and causes G2/M arrest in KB-R cells.

Satraplatin needs to avoid light in the solution, and it is unstable in the alkaline state but stable in the acidic state.Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC50 of 1.36 ± 0.11 μM. Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC50, 7.04 μM), and causes G2/M arrest in KB-R cells.

——

BMS-182751 | BMY-45594 | JM-216

Cell Cycle/DNA Damage

DNA Alkylator

DNA Alkylator

Cancer

Chemotherapeutic

129580-63-8

500.2816

C10H22Cl2N2O4Pt+2

>98% (HPLC)

DMSO: ≥ 33 mg/mL

CC(O[Pt]([NH2]C1CCCCC1)(Cl)(Cl)([NH3])OC(C)=O)=O

Platinum, bis(acetato-κO)amminedichloro(cyclohexanamine)-, (OC-6-43)- (9CI)

(-20℃)

With Ice Pack

≥ 2 years